A5039054307- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Health Systems, Economic Evaluations, Quality of Life
- Allergic Rhinitis and Sensitization
- Reproductive Health and Contraception
- Male Reproductive Health Studies
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Asthma and respiratory diseases
- Spondyloarthritis Studies and Treatments
- Reproductive Health and Technologies
- Economic and Financial Impacts of Cancer
- Pregnancy and Medication Impact
- Autoimmune and Inflammatory Disorders Research
- Reproductive System and Pregnancy
Johnson & Johnson (United States)
2024
Janssen (United States)
2019-2024
Janssen Scientific Affairs (United States)
2019-2024
Prospective data are limited on pregnancy outcomes among women with psoriasis who may be receiving biologic or conventional systemic therapy.To report observed in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).This cohort study used from PSOLAR, a multicenter, disease-based, observational registry evaluating long-term safety clinical for patients eligible to receive treatment biologics and/or therapies. Of 12 090 enrollees, 5456 were (45.1%), 2224 of childbearing age (18-45...
Tumor necrosis factor inhibitors (TNFi) are frequently chosen as the first biologic for patients with psoriatic arthritis (PsA). Given that many PsA TNFi inadequate responders (TNF-IR; either efficacy or intolerance), treatments utilizing alternative mechanisms of action needed. In phase 3 studies, fully human interleukin (IL)-23p19 subunit-inhibitor, guselkumab, was efficacious in active PsA, including TNFi-IR. Efficacy generally consistent between TNFi-naïve and TNFi-experienced cohorts;...
The effects of systemic therapy on mortality risk among patients with psoriasis are not fully understood.To evaluate the impact treatment in enrolled Psoriasis Longitudinal Assessment and Registry.Nested case-control analyses were performed to estimate risk. Cases defined as who died while participating Registry. matched (1:4) controls by age, race, sex, geographic region. Evaluated treatments included methotrexate, ustekinumab, tumor necrosis factor α inhibitors. Exposure was at least 1...
Guselkumab is an anti-interleukin-23 monoclonal antibody for the treatment of moderate-to-severe psoriasis.To evaluate association between dose-response and exposure-response guselkumab in Phase 2 3 studies to optimize dose selection.Serum concentrations (VOYAGE 1 VOYAGE 2) were measured using a validated immunoassay. Efficacy assessments included Physician's Global Assessment (PGA), Investigator's (IGA) Psoriasis Area Severity Index (PASI).In 2, positive relationship was observed PASI PGA...
Patterns of psoriasis characteristics by sex are not fully understood.